Anavex Life Sciences Corp. (AVXL) Hits New 12-Month Low at $2.91
Anavex Life Sciences Corp. (NASDAQ:AVXL) shares reached a new 52-week low on Wednesday . The stock traded as low as $2.91 and last traded at $3.09, with a volume of 1,488,941 shares. The stock had previously closed at $3.37.
AVXL has been the topic of several research reports. FBR & Co restated an “outperform” rating and set a $10.00 price objective on shares of Anavex Life Sciences Corp. in a report on Wednesday. Maxim Group restated a “buy” rating on shares of Anavex Life Sciences Corp. in a report on Monday, June 6th. Finally, Zacks Investment Research upgraded shares of Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Tuesday, May 31st.
The company’s 50 day moving average is $5.58 and its 200 day moving average is $4.86. The stock’s market capitalization is $120.70 million.
Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its earnings results on Wednesday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.10. Analysts expect that Anavex Life Sciences Corp. will post ($0.34) EPS for the current year.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.